# Incumbents vs. challengers: moats, disruption, and the innovator's dilemma
In 2012, Intuitive Surgical sold its da Vinci robot to hospitals for roughly $1.5 million per unit, plus recurring fees on instruments and service. Meanwhile, open-surgery incumbents (the surgeons and the toolmakers who supplied them) held decades of skill, relationships, and trust. Twelve years later, over 12,000 da Vinci systems were installed worldwide (Intuitive company reporting, as of early 2024). The scalpel makers did not lose because their scalpels got worse. They lost because a challenger changed the unit of competition from "the blade" to "the platform."
That is the whole lesson in one scene. Who actually holds power in biotech and medtech, and which moats survive contact with a real challenger?
Not all challengers threaten incumbents the same way. Compare two.
The CRISPR startup vs. legacy pharma. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats, a gene-editing tool) lets you edit DNA directly. Companies like Vertex and CRISPR Therapeutics won FDA (US Food and Drug Administration) and EMA (European Medicines Agency) approval in late 2023 for Casgevy, a one-time treatment for sickle cell disease. A one-time cure attacks the razor-and-blades model of chronic drug sales.
The robotic-surgery upstart vs. open surgery. Intuitive did not sell a molecule. It sold a capital device plus a stream of consumables, and it locked in hospitals through training and installed base.
These are different games. In pharma, the moat is molecular and legal. In devices, the is physical and behavioral. Understanding which is which tells you which moats actually hold.
Before you judge power, name the players. In this sector the chain runs:
Note the split between "approval" and "getting paid." A challenger can win the FDA and still die because no payer reimburses the product. That is a power lever incumbents understand and newcomers underestimate.
A drug patent (typically 20 years from filing, though effective life is shorter after trial time) plus regulatory exclusivity can give a molecule near-total protection. When it expires, generics or biosimilars (near-copies of biologic drugs) crush the price. This is the famous patent cliff: Humira, once the world's top-selling drug, lost US exclusivity in 2023 and faced multiple biosimilars.
In devices, patents matter less. A robot or stapler is a system of hundreds of components. Competitors design around individual claims. The moatmoatA lasting edge over competitors: a resource, capability or position they cannot easily replicate, letting a firm earn above-average returns over time.View full definition → is rarely one patent. It is the integrated whole plus everything below.
Once a hospital buys a da Vinci and trains 20 surgeons on it, switching to a rival robot means retraining, revalidating workflows, and renegotiating service contracts. That is a switching cost moatmoatA lasting edge over competitors: a resource, capability or position they cannot easily replicate, letting a firm earn above-average returns over time.View full definition →, and it is durable. New entrants like Medtronic's Hugo and J&J's Ottava have real technology, yet they fight uphill against an installed base and a trained surgeon population.
Lesson: in medtech, the moatmoatA lasting edge over competitors: a resource, capability or position they cannot easily replicate, letting a firm earn above-average returns over time.View full definition → is often the customer's own sunk cost, not your IP.
Big pharma and medtech field thousands of reps with deep hospital relationships. That is why many challengers do not try to build a rival sales force. They get acquired or partner instead. Vertex commercialized Casgevy itself, but many smaller biotechs license their asset to a big player precisely to rent that distribution moatmoatA lasting edge over competitors: a resource, capability or position they cannot easily replicate, letting a firm earn above-average returns over time.View full definition →.
For complex biologics and cell therapies, manufacturing IS the moatmoatA lasting edge over competitors: a resource, capability or position they cannot easily replicate, letting a firm earn above-average returns over time.View full definition →. Making a personalized cell therapy reproducibly at scale, under GMP (Good Manufacturing Practice, the FDA/EMA quality standard), is brutally hard. That difficulty protects incumbents with plants and protects specialist CMOs who supply everyone.
Clayton Christensen's core insight: incumbents fail not because they are dumb, but because they are rational. They listen to their best customers and protect their most profitable products. That is exactly what makes them slow to adopt something that threatens those products.
Pharma example. A one-time gene therapy that cures a disease cannibalizes a lucrative chronic-treatment franchise. A rational incumbent is slow to build the thing that kills its own annuity. That hesitation is the opening a challenger exploits.
Device example. Early robotic surgery was more expensive and slower than open surgery, and skeptics were loud. To a leading open-surgery toolmaker, it looked like an inferior, overpriced niche. Classic "disruptive technology": worse on the metrics incumbents value, better on a new metric (minimally invasive, less recovery time) that customers came to value more.
Follow the money along the chain, because power shows up as who keeps the margin.
Suppose a surgical robot sells for $1.5 million (illustrative, not a current quote) and generates $2,000 of consumables and service per procedure. A busy hospital does 300 robotic procedures a year.
Recurring revenue per system per year = 300 x $2,000 = $600,000.
Over a 7-year system life, recurring revenue = 7 x $600,000 = $4.2 million.
So the $1.5 million hardware sale is roughly one quarter of the ~$5.7 million lifetime revenue per system. The margin lives in the blades, not the razor. This is why the installed base moatmoatA lasting edge over competitors: a resource, capability or position they cannot easily replicate, letting a firm earn above-average returns over time.View full definition → is so valuable: every locked-in system is a multi-year annuity.
Knowledge check
1. The lesson argues that scalpel makers lost to robotic surgery not because their product got worse. What is the core concept this illustrates?
2. Why does a one-time CRISPR cure like Casgevy pose a distinctive threat to legacy pharma's business model?
3. The lesson distinguishes moats in pharma (molecular and legal) from moats in devices (physical and behavioral). What does this distinction primarily help an analyst do?
4. Select ALL correct answers about how Intuitive Surgical built durability against challengers.
Select all the correct answers.
5. Select ALL correct answers that correctly characterize why 'not all challengers threaten incumbents the same way.'
Select all the correct answers.
Patterns that repeat in this sector:
1. Change the unit of competition. Intuitive competed on "platform + workflow," not on blades. CRISPR firms compete on "cure," not on "chronic control."
2. Rent the moat you cannot build. Small biotechs license to big pharma for distribution and manufacturing rather than fight the sales force head-on.
3. Win reimbursement, not just approval. The die-off point for challengers is often the payer, not the FDA. For deeper reading on how European reimbursement works, see the EMA's overview of the medicines lifecycle.
4. Build the switching cost early. Train the users, embed the workflow, and the installed base becomes your defense once incumbents finally respond.
And how incumbents defend:
The uncomfortable truth: the strongest incumbent defense is often acquisition, which is why "disruption" in this sector frequently ends with the challenger inside the incumbent.